Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer

Anti-Cancer Drugs

Volumn 23, Issue 3, 2012, Pages 335-341

  Gomez, Henry L ^a   Philco, Manuel ^b   Pimentel, Patricia ^b   Kiyan, Miriam ^c,d   Monsalvo, Maria Laura ^c,d   Conlan, Maureen G ^e   Saikali, Khalil G ^e   Chen, Michael M ^e   Seroogy, Joseph J ^e   Wolff, Andrew A ^e   Escandon, Rafael D ^e  

^a INSTITUTO NACIONAL DE ENFERMEDADES NEOPLÁSICAS   (Peru)

^b HOSPITAL NACIONAL ALBERTO SABOGAL SOLOGUREN   (Peru)

^c I3 Research   (Peru)

^d I3 Research   (Argentina)

^e Cytokinetics Inc   (United States)

Author keywords

Breast cancer; Dose limiting toxicity; Ispinesib; Kinesin spindle protein inhibitor; Pharmacokinetics; Phase I

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ISPINESIB; PROGESTERONE RECEPTOR;

ADULT; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; CONTINUOUS INFUSION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HEADACHE; HUMAN; HUMAN TISSUE; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MASTALGIA; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PLEURA METASTASIS; PRIORITY JOURNAL; SIDE EFFECT; SPONTANEOUS ABORTION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ALANINE TRANSAMINASE; ANEMIA; ANTINEOPLASTIC AGENTS; ASPARTATE AMINOTRANSFERASES; BENZAMIDES; BREAST NEOPLASMS; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KINESIN; MAXIMUM TOLERATED DOSE; MIDDLE AGED; QUINAZOLINES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME;

EID: 84858277073     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32834e74d6     Document Type: Article

References (14)

1. Blangy A, Lane HA, d'Hérin P, Harper M, Kress M, Nigg EA, et al. Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell 1995; 83:1159-1169.
2. Marcus AI, Peters U, Thomas SL, Garrett S, Zelnak A, Kapoor TM, Giannakakou P. Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and sensitive cancer cells. J Biol Chem 2005; 280:11569-11577. (Pubitemid 40418469)
3. Lad L, Carson JD, Dhanak D, Jackson JR, Huang PS, Lee Y, et al. Mechanism of inhibition of human KSP by ispinesib. Biochemistry 2008; 47:3576-3585. (Pubitemid 351399246)
4. Purcell JW, Reddy M, Davis J, Martin S, Samayoa K, Vo H, et al. Ispinesib (SB-715992) a kinesin spindle protein (KSP) inhibitor has single agent activity and enhances the efficacy of standard-of-care. In: Therapies in Pre-Clinical Models of Breast Cancer. 31st Annual San Antonio Breast Cancer Symposium (SABCS). San Antonio, TX. December 2008. Poster presentation.
5. Burris HA, Lorusso P, Jones S, Guthrie TM, Orr JB,Williams DD, et al. Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV days 1, 8, 15 q 28 days. ASCO Meeting Abstracts 2004; 22.
6. Heath EI, Alousi A, Eder JP, Valdivieso M, Vasist LS, Appleman L, et al. A phase I dose escalation trial of ispinesib (SB-715992) administered days 1-3 of a 21-day cycle in patients with advanced solid tumors. American Society of Clinical Oncology (ASCO), June, 2006.
7. Chu QS, Holen KD, Rowinsky EK, Wilding G, Volkman JL, Orr JB, et al. Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV Q 21 days. ASCO Meeting Abstracts 2004; 22:2078.
8. Souid A-K, Dubowy RL, Ingle AM, Conlan MG, Sun J, Blaney SM, Adamson PC. A pediatric phase 1 study of ispinesib: a children's oncology group phase 1 consortium study. Pediatr Blood Cancer 2010; 55:1323-1328.
9. LoRusso P, Jones JB, Gadgeel1 S, Willcutt N, Helmke1 W, Orr J, et al. A phase I study to determine the safety and pharmacokinetics of intravenous administration of SB-715992, a novel kinesin spindle protein (KSP) inhibitor, on a once weekly for three consecutive weeks schedule in patients with refractory solid tumors. European CanCer Organization (ECCO) Annual Meeting; 2003.
10. Chu Q, Holen KD, Rowinsky EK, Alberti DB, Monroe P, Volkam JL, et al. A phase I study to determine the safety and pharmacokinetics of IV administered SB-715992, a novel kinesin spindle protein (KSP) inhibitor, in patients with solid tumors. ASCO Meeting Abstracts 2003; 22: Abstract 525.
11. Data on File. GSK 20001 Ispinesib in Locally Advanced and Metastatic Breast Cancer Study Report.
12. Therasse P, Arbuck SG, Eisenhauer EA,Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-216. (Pubitemid 30099779)
13. Common Terminology Criteria for Adverse Events CTCAE (v 3.0). National Cancer Institute. Available at http://ctep.cancer.gov/protocoldevelopment/ electronic-applications/docs/ctcaev3.pdf. [Accessed 29 May 2011].
14. O'Connor OA, Gerecitano J, Van Deventer H, Afanasyev B, Hainsworth J, Chen MM, et al. A Phase I/II Trial of the Kinesin Spindle Protein (KSP) Inhibitor SB-743921 Dosed Q14D without and with Prophylactic G-CSF in Non-Hodgkin Lymphoma (NHL) or Hodgkin Lymphoma (HL). American Society of Hematology, 51st Annual Meeting and Exposition. December 2009. Poster presentation.